Townsend & Associates Inc Purchases 2,320 Shares of The Clorox Company (NYSE:CLX)

Townsend & Associates Inc grew its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 19.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,232 shares of the company's stock after acquiring an additional 2,320 shares during the quarter. Townsend & Associates Inc's holdings in Clorox were worth $1,973,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Redwood Park Advisors LLC acquired a new position in Clorox during the fourth quarter worth $26,000. Millstone Evans Group LLC bought a new stake in Clorox during the 4th quarter worth about $31,000. Wood Tarver Financial Group LLC acquired a new position in shares of Clorox during the 4th quarter worth about $31,000. GKV Capital Management Co. Inc. bought a new position in shares of Clorox in the 4th quarter valued at about $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Clorox in the fourth quarter valued at about $33,000. 78.53% of the stock is owned by institutional investors.

Clorox Price Performance

Shares of CLX opened at $119.09 on Monday. The Clorox Company has a fifty-two week low of $117.35 and a fifty-two week high of $171.37. The firm has a market capitalization of $14.68 billion, a PE ratio of 21.38, a PEG ratio of 2.70 and a beta of 0.54. The company's 50-day moving average is $131.21 and its 200-day moving average is $145.00. The company has a debt-to-equity ratio of 13.07, a current ratio of 0.74 and a quick ratio of 0.44.

Clorox (NYSE:CLX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). The firm had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 9.89% and a return on equity of 324.23%. Clorox's revenue for the quarter was down 8.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.71 EPS. Equities analysts forecast that The Clorox Company will post 7.15 EPS for the current year.

Insider Activity at Clorox

In other Clorox news, Director Pierre R. Breber acquired 4,000 shares of the business's stock in a transaction on Wednesday, May 7th. The stock was purchased at an average price of $136.57 per share, with a total value of $546,280.00. Following the acquisition, the director now directly owns 4,000 shares of the company's stock, valued at approximately $546,280. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Evercore ISI set a $140.00 price target on Clorox and gave the company an "underperform" rating in a research report on Tuesday, May 6th. Jefferies Financial Group cut their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a report on Thursday. JPMorgan Chase & Co. lowered their target price on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Morgan Stanley cut their price target on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Finally, Barclays lowered their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research note on Wednesday, May 7th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Clorox presently has a consensus rating of "Hold" and a consensus target price of $149.50.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.